Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of meetings25-02-2022
25-02-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of meeting21-02-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Meetings16-02-2022
Buy Gland Pharma; target of Rs 4240: Motilal Oswal
Motilal Oswal is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 4240 in its research report dated January 22, 2022.10-02-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings call Transcript for Q3FY2228-01-2022
Gland Pharma's R&D costs hit profitability during Q3
Kotak Institutional Equities expects Gland's injectables prowess to continue to lead to a successful scale up across non-US markets, albeit at the cost of margins24-01-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Meetings24-01-2022
Earnings Call for Q3FY22 of Gland Pharma
Conference Call with Gland Pharma Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.23-01-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Unaudited Financial Results for the Quarter and Nine months ended December 31, 202122-01-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report for the Quarter ending December 31, 202121-01-2022